Prognostic factors in breast cancer: Current and new predictors of metastasis

Journal of Mammary Gland Biology and Neoplasia

Volumn 6, Issue 4, 2001, Pages 375-392

  Hayes, Daniel F ^a   Isaacs, Claudine ^b   Stearns, Vered ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

Adjuvant systemic therapy; Breast cancer; Prognostic factors; Tumor marker utility grading system

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; CATENIN; CATHEPSIN D; CYCLIN D; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; OSTEOPONTIN; PACLITAXEL; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROGESTERONE RECEPTOR; PROSTATE SPECIFIC ANTIGEN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P53; TAXANE DERIVATIVE; THROMBOPLASTIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TRASTUZUMAB; UNINDEXED DRUG; UROKINASE; UVOMORULIN; VASCULOTROPIN; TUMOR MARKER;

AXILLARY LYMPH NODE; BONE MARROW METASTASIS; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER GRADING; CANCER HORMONE THERAPY; CANCER INVASION; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE; CELL DEATH; CELL PROLIFERATION; CLINICAL TRIAL; DNA SYNTHESIS; DRUG RESPONSE; EVIDENCE BASED MEDICINE; FLOW CYTOMETRY; HIGH RISK PATIENT; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; META ANALYSIS; METASTASIS; PREDICTION; PROGNOSIS; RECURRENCE RISK; REVIEW; SIDE EFFECT; SYSTEMIC THERAPY; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR VASCULARIZATION; TUMOR VOLUME; BREAST TUMOR; FEMALE; METABOLISM;

BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM METASTASIS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0035495969     PISSN: 10833021     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1014778713034     Document Type: Review

References (96)

1. S. Nass, I. C. Henderson, and J. C. Lashoff (2001). Mammography and Beyond: Developing Technologies for the Early Detection of Breast Cancer, National Academy Press, Washington, DC.
2. Early Breast Cancer Trialist's Collaborative Group (1998). Polychemotherapy for early breast cancer: An overview of the randomized trials. Lancet 352:930 942.
3. Early Breast Cancer Trialist's Collaborative Group (1998). Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 351:1451-1467.
4. Early Breast Cancer Trialists Collaborative Group (1996). Ovarian ablation in early breast cancer: Overview of the randomised trials. Lancet 348:1189-1196.
5. Early Breast Cancer Trialists' Collaborative Group (2000). Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 355:1757-1770.
6. R. Peto, J. Boreham, M. Clarke, C. Davies, and V. Beral (2000). UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 355:1822.
7. W. S. Halsted (1894-95). The results of operations for the cure of cancer of the breast performed at the Johns Hopkins Hospital from June, 1889, to January, 1894. Johns Hopkins Hosp. Rep. iv:297-350.
8. American Joint Committee on Cancer (1997). In I. Fleming, J. Cooper, D. Henson, R. Hutter, B. J. Kennedy, G. Murphy, B. O'Sullivan, L. Sobin, and J. Yarbro (eds.), AJCC Cancer Staging Handbook, Breast, 5th edn., Vol. 1, Lippincott-Raven, Philadelphia, pp. 171-180.
9. D. F. Hayes, R. Bast, C. E. Desch, H. Fritsche, N. E. Kemeny, J. Jessup, G. Y. Locker, J. Macdonald, R. G. Mennel, L. Norton, P. Ravdin, S. Taube, and R. Winn (1996). A tumor marker utility grading system (TMUGS): A framework to evaluate clinical utility of tumor markers. J. Natl. Cancer Inst. 88:1456-1466.
10. R. Simon and D. G. Altman (1994). Statistical aspects of prognostic factor studies in oncology. Br. J. Cancer 69:979-985.
11. D. G. Altman and G. H. Lyman (1998). Methodological challenges in the evaluation of prognostic factors in breast cancer. Breast Cancer Res. Treat. 52:289-303.
12. W. L. McGuire (1991). Breast cancer prognostic factors: Evaluation guidelines. J. Natl. Cancer Inst. 83:154-155.
13. G. Gasparini, F. Pozza, and A. L. Harris (1993). Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J. Natl. Cancer Inst. 85: 206-1219.
14. D. F. Hayes, B. Trock, and A. Harris (1998). Assessing the clinical impacT of prognostic factors: When is "statistically significant" clinically useful? Breast Cancer Res. Treat. 52:305-319.
15. W. L. McGuire and G. M. Clark (1992). Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N. Engl. J. Med. 326:1756-1761.
16. G. Gasparini (1998). Prognostic variables in node-negative and node-positive breast cancer [editorial]. Breast Cancer Res. Treat. 52:321-331.
17. ASCO Expert Panel (1996). Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer: Report of the american society of clinical oncology expert panel. J. Clin. Oncol. 14: 843-2877.
18. ASCO Expert Panel (1998). 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. J. Clin. Oncol. 16:793-795.
19. R. C. Bast Jr., P. Ravdin, D. F. Hayes, S. Bates, H. Fritsche Jr., J. M. Jessup, N. Kemeny, G. Y. Locker, R. G. Mennel, and M. R. Somerfield (2001). 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the american society of clinical oncology. J. Clin. Oncol. 19: 865-1878.
20. C. Isaacs, V. Stearns, and D. F. Hayes (2001). New prognostic factors for breast cancer recurrence. Semin. Oncol. 28:53-67.
21. P. Ravdin, I. Siminoff, and J. Harvey (1998). Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy. J. Clin. Oncol. 16:515-521.
22. A. S. Coates and R. J. Simes (1992). Patient Assessment of Adjuvant Treatment in Operable Breast Cancer, Wiley, New York.
23. C. Lindley, S. Vasa, T. Sawyer, and E. Winer (1998). Quality of life and preferences for treatment following systemic adjuvant therapy for early stage breast cancer. J. Clin. Oncol. 16:1380-1387.
24. S. Rajagopal, P. J. Goodman, and I. F. Tannock (1994). Adjuvant chemotherapy for breast cancer: Discordance between physicians' perception of benefit and the results of clinical trials. J. Clin. Oncol. 12:1296-1304.
25. P. M. Ravdin, L. A. Siminoff, G. J. Davis, M. B. Mercer, J. Hewlett, N. Gerson, and H. L. Parker (2001). Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J. Clin. Oncol. 19:980-991.
26. I. C. Henderson, D. Berry, G. Demetri, C. Cirrincione, L. Goldstein, S. Martino, J. Ingle, M. Cooper, G. Canellos, E. Borden, G. Fleming, J. Holland, S. Graziano, J. Carpenter, H. Muss, and L. Norton (1998). Improved disease-free and over-all survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer. Proc. Am. Soc. Clin. Oncol. 17:101a.
27. C. L. Carter, C. Allen, and D. E. Henson (1989). Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63:181-187.
28. P. P. Rosen, S. Groshen, D. W. Kinne, and L. Norton (1993). Factors influencing prognosis in node-negative breast carcinoma: Analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. J. Clin. Oncol. 11:2090-2100.
29. C. A. Quiet, D. J. Ferguson, R. R. Weichselbaum, and S. Hellman (1995). Natural history of node-negative breast cancer: A study of 826 patients with long-term follow-up. J. Clin. Oncol. 13:1144-1151.
30. J. F. Simpson and D. L. Page (1994). Status of breast cancer prognostication based on histopathologic data. Am. J. Clin. Pathol. 102:S3-S8.
31. P. P. Rosen, S. Groshen, P. E. Saigo, D. W. Kinne, and S. Hellman (1989). Pathological prognostic factors in Stage I (T1N0M0) and Stage II (T1N1M0) breast carcinoma: A study of 644 patients with median follow-up of 18 years. J. Clin. Oncol. 7:1239-1251.
32. H. J. Bloom and W. W. Richardson (1957). Histological grading and prognosis in breast cancer. Br. J. Cancer 11:359-377.
33. C. W. Elston and 1. O. Ellis (1991). Pathological prognostic factors in breast cancer. 1. The value of histological gade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 19:403-409.
34. B. Fisher, C. Redmond, E. R. Fisher, and R. Caplan (1988). Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: Findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J. Clin. Oncol. 6:1076-1087.
35. G. Contesso, H. Mouriesse, S. Friedman, J. Genin, D. Sarrazin, and J. Rouesse (1987). The importance of histologic grade in long-term prognosis of breast cancer: A study of 1,010 patients, uniformly treated at the Institut Gustave-Roussy. J. Clin. Oncol. 5:1378-1386.
36. J. W. Yarbro, D. L. Page, L. P. Fielding, E. E. Partridge, and G. P. Murphy (1999). American Joint Committee on Cancer prognostic factors consensus conference. Cancer 86:2436-2446.
37. P. L. Fitzgibbons, D. L. Page, D. Weaver, A. D. Thor, D. C. Allred, G. M. Clark, S. G. Ruby, F. O'Malley, J. F. Simpson, J. L. Connolly, D. F. Hayes, S. B. Edge, A. Lichter, and S. J. Schnitt (2000). Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch. Pathol. Lab. Med. 124:966-978.
38. K. Gilchrest, L. Kalish, V. Gould, H. S. J. Imbriglia, W. Levy, A. Patchefsky, D. Penner, J. Pickren, J. Roth, R. Schinella, I. Schwartz, and J. Wheeler (1985). Interobserver reproducibility of histopathological features in stage II breast cancer. Breast Cancer Res. Treat. 5:3-10.
39. L. W. Dalton, S. E. Pinder, C. E. Elston, I. O. Ellis, D. L. Page, W. D. Dupont, and R. W. Blamey (2000). Histologic grading of breast cancer: Linkage of patient outcome with level of pathologist agreement. Mod. Pathol. 13:730-735.
40. D. L. Page, W. D. Dupont, R. A. Jensen, and J. F. Simpson (1998). When and to what end do pathologists agree? J. Natl. Cancer Inst. 90: 8-89.
41. A. M. Neville, R. Bettelheim, R. D. Gelber, J. Save-Soderbergh, B. W. Davis, R. Reed, J. Torhorst, R. Golouh, H. F. Peterson, K. N. Price, et al. (1992). Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. The International (Ludwig) Breast Cancer Study Group. J. Clin. Oncol. 10:696-705.
42. W. L. McGuire, A. K. Tandon, D. C. Allred, G. C. Chamness, and G. M. Clark (1990). How to use prognostic factors in axillary node-negative breast cancer patients. J. Natl. Cancer Inst. 82:1006-1015.
43. S. G. Hilsenbeck, P. M. Ravdin, C. A. de Moor, G. C. Chamness, C. K. Osborne, and G. M. Clark (1998). Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res. Treat. 52:227-237.
44. C. R. Wenger and G. M. Clark (1998). S-phase fraction and breast cancer - a decade of experience. Breast Cancer Res. Treat. 51: 55-265.
45. L. Hutchins, S. Green, P. Ravdin, D. Lew, S. Martino, M. Abeloff, A. Lyss, I. C. Henderson, C. Allred, S. Dakhil, L. Pierce, W. Goodwin, J. Caton, S. Rivkin, R. Chapman, and K. Osborne (1998). CMF vs. CAF with and without tamoxifen in high-risk node-negataive breast cancer patients and a natural history follow-up study in low-risk node-negative patients: First results of intergroup trial INT0102. Proc. Am. Soc. Clin. Oncol. 17:1a.
46. R. W. Brown, C. D. Allred, G. M. Clark, C. K. Osborne, and S. G. Hilsenbeck (1996). Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clin. Cancer Res. 2: 85-592.
47. A. D. Thor, S. Liu, D. H. Moore II, and S. M. Edgerton (1999). Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer. J. Clin. Oncol. 17:470-477.
48. D. Amadori and R. Silvestrini (1998). Prognostic and predictive value of thymidine labelling index in breast cancer. Breast Cancer Res. Treat. 51:267-281.
49. L. Dressler, K. Conway, J. Geradts, S. Edminston, D. Cowan, M. Burroughs, L. Cui, M. He, J. Pang, K. Mistry, S. Drouin, Y. Li, J. Tse, R. Millikan, and B. Newman (1999). Immunohistochemistry can accurately detect missense mutations in the p53 gene: A comparison with gene sequencing in 196 breast cancers. Proc. Am. Assoc. Cancer Res. 40:690a.
50. C. MacGeoch, G. Turner, L. Bobrow, D. M. Barnes, D. Bishop, and N. Spurr (1995). Heterogeneity in Li-Fraumeni families: P53 mutation analysis and immunohistochemical staining. J. Med. Genet. 32: 86-190.
51. P. D. Pharoah, N. E. Day, and C. Caldas (1999). Somatic mutations in the p53 gene and prognosis in breast cancer: A meta-analysis. Br. J. Cancer 80:1968-1973.
52. J. Reed (1994). Bcl-2 and the regulaton of programmed cell death. J. Cell Biol. 124:1-6.
53. S. Krajewski, A. Thor, S. Edgerton, D. Moore, M. Krajewska, and J. Reed (1997). Analysis of bax and bcl-2 in p53-immunopositive breast cancers. Clin. Cancer Res. 3:199-208.
54. S. Krajewski, C. Blomqvist, K. Franssila, M. Krajewska, V. M. Wasenius, E. Niskanen, S. Nordling, and J. C. Reed (1995). Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res. 55:4471-4478.
55. O. I. Olopade, M. O. Adeyanju, A. R. Safa, F. Hagos, R. Mick, C. B. Thompson, and W. M. Recant (1997). Overexpression of BCL-x protein in primary breast cancer is associated with high tumor grade and nodal metastases. Cancer J. Sci. Am. 3:230-237.
56. C. Gillett, P. Smith, W. Gregory, M. Richards, R. Millis, G. Peters, and D. Barnes (1996). Cyclin D1 and prognosis in human breast cancer. Int. J. Cancer 69:92-99.
57. D. M. Barnes and C. E. Gillett (1998). Cyclin D1 in breast cancer. Breast Cancer Res. Treat. 52:1-15.
58. R. Seshadri, C. S. Lee, R. Hui, K. McCaul, D. J. Horsfall, and R. L. Sutherland (1996). Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis. Clin. Cancer Res. 2:1177-1184.
59. A. L. Schechter, D. F. Stern, L. Vaidyanathan, S. J. Decker, J. A. Drebin, M. I. Greene, and R. A. Weinberg (1984). The neu oncogene: An erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 312:513-516.
60. D. J. Slamon, G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich, and W. L. McGuire (1987). Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 77-182.
61. B. J. Trock, H. Yamauchi, M. Brotzman, V. Stearns, and D. F. Hayes (2000). c-erbB-2 as a prognostic factor in breast cancer: A meta-analysis. Proc. Am. Soc. Clin. Oncol. 19:97a.
62. H. Yamauchi, V. Stearns, and D. F. Hayes (2001). When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J. Clin. Oncol. 19:2334-2356.
63. M. F. Press, L. Bernstein, P. A. Thomas, L. F. Meisner, J. Y. Zhou, Y. Ma, G. Hung, R. A. Robinson, C. Harris, A. El-Naggar, D. J. Slamon, R. N. Phillips, J. S. Ross, S. R. Wolman, and K. J. Flom (1997). HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas. J. Clin. Oncol. 15:2894-2904.
64. K. Siziopikou, S. Schnitt, J. Connolly, and D. F. Hayes (1999). Detection and significance of occult axillary metastatic disease in breast cancer patients. Breast J. 5:221-229.
65. D. Krag, D. Weaver, T. Ashikaga, F. Moffat, V. S. Klimberg, C. Shriver, S. Feldman, R. Kusminsky, M. Gadd, J. Kuhn, S. Harlow, and P. Beitsch (1998). The sentinel node in breast cancer - a multicenter validation study. N. Eng. J. Med. 339:941-946.
66. A. E. Giuliano, R. C. Jones, M. Brennan, and R. Statman (1997). Sentinel lymphadenectomy in breast cancer. J. Clin. Oncol. 15: 345-2350.
67. N. Hansen, B. J. Grube, W. Te, M. L. Brennan, R. Turner, and A. E. Giuliano (2001). Clinical significance of axillary micrometastases in breast cancer: How small is too small. Proc. Am. Soc. Clin. Oncol. 20:223a.
68. I. Funke and W. Schraut (1998). Meta-analyses of studies on bone marrow micrometastases: An independent prognostic impact remains to be substantiated. J. Clin. Oncol. 16:557-566.
69. I. J. Diel, M. Kaufmann, S. D. Costa, R. Holle, G. von Minckwitz, E. F. Solomayer, S. Kaul, and G. Bastert (1996). Micrometastatic breast cancer cells in bone marrow at primary surgery: Prognostic value in comparison with nodal status. J. Natl. Cancer Inst. 88: 652-1658.
70. S. Braun, K. Pantel, P. Muller, W. Janni, F. Hepp, C. R. Kentenich, S. Gastroph, A. Wischnik, T. Dimpfl, G. Kindermann, G. Riethmuller, and G. Schlimok (2000). Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N. Engl. J. Med. 342:525-533.
71. G. Gebauer, T. Fehm, E. Merkle, E. P. Beck, N. Lang, and W. Jager (2001). Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: Clinical outcome during long-term follow-up. J. Clin. Oncol. 19:3669-3674.
72. J. Folkman (1990). What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. 82:4-6.
73. N. Weidner, J. Folkman, F. Pozza, P. Bevilacqua, E. Allred, S. Meli, and G. Gasparini (1992). Tumor angiogenesis: A new significant and independent prognostic indicator in early stage breast carcinoma. J. Natl. Cancer Inst. 84:1875-1887.
74. G. Gasparini (2001). Clinical significance of determination of surrogate markers of angiogenesis in breast cancer. Crit. Rev. Oncol. Hematol. 37:97-114.
75. A. J. Guidi, D. Berry, G. Broadwater, B. Helmchen, I. Bleiweiss, D. Budman, I. C. Henderson, L. Norton, and D. F. Hayes (submitted). Association ofangiogenesis and disease outcome in node-positive breast cancer patients treated with adjuvant CAF chemotherapy: A CALGB correlative science study from protocols 8541/8869. J. Clin. Oncol. 20:732-742.
76. G. Gasparini, M. Toi, M. Gion, P. Verderio, R. Dittadi, M. Hanatani, I. Matsubara, O. Vinante, E. Bonoldi, P. Boracchi, C. Gatti, H. Suzuki, and T. Tominaga (1997). Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J. Natl. Cancer Inst. 89:139-147.
77. U. Eppenberger, W. Kueng, J. M. Schlaeppi, J. L. Roesel, C. Benz, H. Mueller, A. Matter, M. Zuber, K. Luescher, M. Litschgi, M. Schmitt, J. A. Foekens, and S. Eppenberger-Castori (1998). Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients. J. Clin. Oncol. 16:3129-3136.
78. B. R. Westley and F. E. May (1996). Cathepsin D and breast cancer. Eur. J. Cancer 32A:15-24.
79. P. M. Ravdin, C. A. de Moor, S. G. Hilsenbeck, M. K. Samoszuk, P. M. Vendely, and G. M. Clark (1997). Lack of prognostic value of cathepsin D levels for predicting short term outcomes of breast cancer patients. Cancer Lett. 116:177-183.
80. G. Ferrandina, G. Scambia, F. Bardelli, P. Benedetti Panici, S. Mancuso, and A. Messori (1997). Relationship between cathepsin-D content and disease-free survival in node-negative breast cancer patients: A meta-analysis. Br. J. Cancer 76:661-666.
81. R. W. Stephens, N. Brunner, F. Janicke, and M. Schmitt (1998). The urokinase plasminogen activator system as a target for prognostic studies in breast cancer. Breast Cancer Res. Treat. 52:99-111.
82. J. A. Foekens, H. A. Peters, M. P. Look, H. Portengen, M. Schmitt, M. D. Kramer, N. Brunner, F. Janicke, M. E. Meijer-van Gelder, S. C. Henzen-Logmans, W. L. van Putten, and J. G. Klijn (2000). The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res. 60:636-643.
83. F. Janicke, A. Prechtl, C. Thomssen, N. Harbeck, C. Meisnet, M. Untch, C. G. Sweep, H. K. Selbmann, H. Graeff, and M. Schmitt (2001). Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J. Natl. Cancer Inst. 93:913-920.
84. D. W. Visscher, F. Sarkar, P. LoRusso, W. Sakr, S. Ottosen, S. Wykes, and J. D. Crissman (1993). Immunohistologic evaluation of invasion-associated proteases in breast carcinoma. Mod. Pathol. 6:302-306.
85. A. B. Tuck, F. P. O'Malley, H. Singhal, J. F. Harris, K. S. Tonkin, N. Kerkvliet, Z. Saad, G. S. Doig, and A. F. Chambers (1998). Osteopontin expression in a group of lymph node negative breast cancer patients. Int. J. Cancer 79:502-508.
86. R. Heimann and S. Hellman (2000). Individual characterisation of the metastatic capacity of human breast carcinoma. Eur. J. Cancer 36:1631-1639.
87. R. Heimann, F. Lan, R. McBride, and S. Hellman (2000). Separating favorable from unfavorable prognostic markers in breast cancer: The role of E-cadherin. Cancer Res. 60:298-304.
88. R. Heimann, D. J. Ferguson, and S. Hellman (1998). The relationship between nm23, angiogenesis, and the metastatic proclivity of node-negative breast cancer. Cancer Res. 58:2766-2771.
89. H. Yu, M. A. Levesque, G. M. Clark, and E. P. Diamandis (1999). Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination. Br. J. Cancer 81:490-495.
90. A. Remacle, K. McCarthy, A. Noel, T. Maguire, E. McDermott, N. O'Higgins, J. M. Foidart, and M. J. Duffy (2000). High levels of TIMP-2 correlate with adverse prognosis in breast cancer. Int. J. Cancer 89: 18-121.
91. T. Ueno, M. Toi, M. Koike, S. Nakamura, and T. Tominaga (2000). Tissue factor expression in breast cancer tissues: Its correlation with prognosis and plasma concentration. Br. J. Cancer 83:164-170.
92. R. Yoshida, N. Kimura, Y. Harada, and N. Ohuchi (2001). The loss of E-cadherin, alpha- and beta-catenin expression is associated with metastasis and poor prognosis in invasive breast cancer. Int. J. Oncol. 18:513-520.
93. M. Emi, M. Yoshimoto, T. Sato, S. Matsumoto, Y. Utada, I. Ito, K. Minobe, T. Iwase, T. Katagiri, K. Bando, F. Akiyama, Y. Harada, K. Fukino, G. Sakamoto, M. Matsushima, A. Iida, T. Tada, H. Saito, Y. Miki, F. Kasumi, and Y. Nakamura (1999). Allelic loss at 1p34, 13q12, 17p13.3, and 17q21.1 correlates with poor postoperative prognosis in breast cancer. Genes Chromosomes Cancer 26:134-141.
94. Y. Utada, M. Emi, M. Yoshimoto, F. Kasumi, F. Akiyama, G. Sakamoto, S. Haga, T. Kajiwara, and Y. Nakamura (2000). Allelic loss at 1p34-36 predicts poor prognosis in node-negative breast cancer. Clin. Cancer Res. 6:3193-3198.
95. R. Hui, R. D. Macmillan, F. S. Kenny, E. A. Musgrove, R. W. Blamey, R. I. Nicholson, J. F. Robertson, and R. L. Sutherland (2000). INK4a gene expression and methylation in primary breast cancer: Overexpression of p16INK4a messenger RNA is a marker of poor prognosis. Clin. Cancer Res. 6:2777-2787.
96. X. Yang, L. Yan, and N. E. Davidson (2001). DNA methylation in breast cancer. Endocr. Relat. Cancer 8:115-127.